Policy Makers

This document provides a generic framework for implementing TB diagnostics. Topics covered include managerial, technical, and operational processes required for developing and implementing a national strategy for TB laboratories.

The objectives of this document are to describe the best practices in engaging different health providers and partners in the management of drug-resistant TB patients and to describe the necessary components in planning and implementing a public-private mix for the management of drug-resistant TB.

This document outlines the United States Government's global TB strategy.

This report presents summary data for U.S. TB cases reported to the Division of TB Elimination, CDC, during 2014.

This infographic was adapted from the CDC Division of Tuberculosis Elimination’s Take on TB infographic. Staff at the New Mexico Department of Health adapted the resource to include statistics specific to their state. Additional information, such as the cost to treat latent TB infection, was also added.

This is the 20th global report on tuberculosis (TB) published by WHO in a series that started in 1997. It provides a comprehensive and up-to-date assessment of the TB epidemic and progress in implementing and financing TB prevention, care and control at global, regional and country levels using data reported by 200 countries and territories that account for over 99% of the world’s TB cases.

This document highlights strategic directions to integrate digital health into TB prevention and care activities in support of WHO’s End TB Strategy.

This document shares best practices in engagement of health care providers in programmatic management of drug-resistant tuberculosis that have been documented in different countries and regions and implemented by different stakeholders. Case studies presented in the document are lessons learned for scale-up of public-private mix for the management of drug-resistant TB at country level.

This report analyses the factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs. Detailed pricing profiles of key DR-TB drugs are also provided.

This report details the steps that governments of countries with high burdens of TB-HIV and their partners have taken to turn a coordinated response to TB-HIV into reality at the country level, as well as the remaining gaps.